益肾蠲痹丸治疗强直性脊柱炎的临床研究

Clinical Study on Treatment of Ankylosing Spondylitis with Yishen Juanbi Pill

目的:探讨益肾蠲痹丸对强直性脊柱炎(AS)的治疗作用。方法:入选AS确诊患者105例,随机分为治疗组64例,对照组41例,治疗组在对照组西药治疗基础上同时服用益肾蠲痹丸,比较治疗3个月后两组强直性脊柱炎Bath指数、血沉、C反应蛋白及6个月后骨密度的变化。结果:治疗3个月后,治疗组患者Bath疾病活动指数、Bath功能指数和血沉、C反应蛋白水平均明显下降,下降幅度优于对照组(P<0.05),Bath测量指数下降亦优于对照组,但无统计学差异(P>0.05);腰椎骨密度减低在AS患者中较为普遍,发生率为56.7%,益肾蠲痹丸对腰椎骨量丢失有改善作用,对骨密度的升高优于对照组(P<0.05)。结论:益肾蠲痹丸在AS治疗中疗效确切,其获效机制与其具有显著抗炎镇痛以及减少脊柱骨丢失等有关。

Objectives.To investigate the effect of treatment of ankylosing spondylitis （AS） with Yishen Juanbi pill. Methods ：105 patients with AS were randomly divided into two groups ：the treatment group with 64 patients and the control group with 41 patients. Patients in the control group were treated with regular medicine, and Yishen Juanbi pill was added to the treatment group. The Bath index, erythrocyte sedimentation rate （ESR）, C - neactveprotein （CRP） were tested before the treatment began and 3 months later,and BMD （bone mineral density） were measured before the treatment began . and 6 months later. Results：3 months after treatment began, Bath ankylosing spondylitis disease activity index （BASDAI）, Bath ankylosing spondylitis function index（ BASFI）, ESR and CRP in the treatment group were significantly decreased, and had a statistical significance compared with the control group（ P 〈 0.05 ）. There also a larger reduction of Bath ankylosing spondylitis measurement index （BASMI） in the treatment group compared with the control group,but there was no statistical significance（ P 〉 0.05）. The incidence of lumbar BMD reduction in AS patients is 56.7%. There was significant improvement of the lumbar BMD reduction in the treatment group（P 〈0.05）. Conclusion：Yishen Juanbi pill has an exact curative effect on AS patients. The effect mechanism is the significant anti -inflammatory and analgesic effect and reducing spinal bone loss.